Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975037 | 0.81 | SIGMAR1 (0.48) | HDAC3CYP3A4KMT2ACYP1A2CYP2D6 | |
| SCHEMBL19974816 | 0.77 | HDAC3 (0.41) | SCN9AHDAC3KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL19975305 | 0.77 | CXCR3 (0.41) | CTSDCYP3A4KMT2ACYP1A2CYP2D6 | |
| SCHEMBL3786803 | 0.76 | PKM (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3786809 | 0.76 | PKM (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL19974688 | 0.73 | CTSL (0.41) | CTSDSIGMAR1 | |
| SCHEMBL19975315 | 0.73 | NAPEPLD (0.42) | HDAC3CTSDKMT2AALDH1A1MEN1 | |
| SCHEMBL3786533 | 0.72 | ALDH1A1 (0.47) | HDAC3KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL3786538 | 0.72 | ALDH1A1 (0.47) | HDAC3KMT2AALDH1A1MEN1HPGD | |
| SCHEMBL28897894 | 0.72 | CASP3 (0.54) | CYP3A4KMT2ACYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | CA12 3472/4885CA1 3962/4885CA2 2905/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | CA12 3451/4885CA1 4029/4885CA2 2926/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | CA12 3472/4885CA1 3962/4885CA2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.